[libribook.com] Traumatic Scar Tissue Management 1st Edition
large enough, a voltage spike is produced and the signal is ultimately transmittedto the brain. When certain neurons fire too easily or too often hyperexcitablilitycan arise (Ratté et al. 2014).Injury-induced hyperexcitability is not limited to nociceptors. Hyperexcitabilityalso develops in myelinated afferents that normally convey innocuousinformation (e.g. normal movement and touch) and under neuropathicconditions, mechanical allodynia can occur (Campbell et al. 1988, Koltzenburget al. 1994, Devor 2009, King et al. 2011, Ratté et al. 2014).Hyperexcitability can make something perceived as painful feel even worse(hyperalgesia), or it can make things hurt that should not (allodynia). Accordingto Ratté et al. (2014), increasing the flow of ions through the cell membrane caneventually result in a ‘tipping point’ to be crossed, which triggers a change in thevoltage spiking pattern (i.e. lowering of threshold and increase in firing rate –see Fig. 4.11). However, as several different types of ion channels contribute tothe current, there are several different ways in which the tipping point can becrossed. This ability to produce the same result by multiple means is a commonfeature of complex systems. It makes systems more robust, as a given result canstill be achieved if one particular attempt to achieve this result fails. The work ofRatté and colleagues helps to explain why drugs that target just one type of ionchannel may fail to relieve neuropathic pain as maladaptive changes in any oneof several other ion channels may circumvent the therapeutic effect (Ratté et al.2014).Neuropathic pain is notoriously difficult to treat as it does not respond well tocommon painkillers. Ratté and colleagues suggest that a paradigm shift will beneeded to effectively treat neuropathic pain - recommending that treatmentsaimed at restoring normal regulation of excitability, rather than targeting ionchannels themselves, may present the best course of action (Ratté et al. 2014).TermAllodyniaFasciagenicPainDefinition, mechanism, characteristics and other important informationPain due to a stimulus that does not normally provoke pain – an unexpected pain response associatedwith different types of somatosensory stimuli applied to different tissues. A consequence of neuralhyperexcitationBecause fascia has been largely overlooked as a potential pain generator and because scarringimpacts fascia, specific consideration is given here. Fascia contains type C nociceptors and some ofthe free nerve endings in fascia are substance P-containing receptors, commonly assumed to benociceptive and rendering fascia a potential pain generator (Tesarz 2009). And, as previously noted,neurofascial coverings are innervated by nervi nervorum
Pathophysiological considerationElevated concentrations of biochemical substances associated with pain, inflammation and intercellular signaling arefound at active MTrP locations (e.g. inflammatory mediators, neuropeptides, catecholamines, pro-inflammatorycytokines, pain modulators). Increased levels of pain modulators, such as Substance P and bradykinins, are plausibleexplanations for the occurrence of pain associated with active MTrPs (Shah et al. 2005).
- Page 337 and 338: Figure 4.1B Functional composition
- Page 339 and 340: Pathophysiological ConsiderationWhe
- Page 341 and 342: Figure 4.2Dorsal and ventral compon
- Page 344 and 345: Figure 4.3Neuron anatomy: most neur
- Page 346 and 347: Figure 4.4Classic axon to dendrite
- Page 349: Figure 4.6PNS efferent (motor) and
- Page 352 and 353: Clinical ConsiderationPSNS afferent
- Page 354 and 355: Clinical ConsiderationSNS activatio
- Page 357 and 358: Figure 4.8Anterior and posterior di
- Page 360 and 361: Figure 4.9Neurofascial envelopes.
- Page 362 and 363: Pathophysiological ConsiderationA n
- Page 364 and 365: Clinical ConsiderationThere is an e
- Page 366 and 367: Clinical ConsiderationDiane Jacobs
- Page 368 and 369: Clinical ConsiderationIt appears th
- Page 370 and 371: Clinical ConsiderationAlthough musc
- Page 372 and 373: Clinical ConsiderationThe form of s
- Page 374 and 375: Example 2Ruffini stimulation result
- Page 376 and 377: Table 4.1Summary of receptor typolo
- Page 378 and 379: • Therapeutic outcome include enh
- Page 380 and 381: NS FunctionThe primary functions of
- Page 382 and 383: Clinical ConsiderationMechanorecept
- Page 384 and 385: Clinical ConsiderationIn addition t
- Page 386 and 387: Clinical ConsiderationManual techni
- Page 390 and 391: PathophysiologicalconsiderationUnde
- Page 392 and 393: Table 4.2Important pain terms. Vari
- Page 394 and 395: Clinical ConsiderationAccording to
- Page 396 and 397: disorders (diabetes mellitus), drug
- Page 398 and 399: forms of negative plasticity includ
- Page 400 and 401: Central and peripheral sensitizatio
- Page 402 and 403: Clinical ConsiderationFollowing per
- Page 404 and 405: ExampleHypersensitive nerves (assoc
- Page 406 and 407: Example 1Hypersensitized nerve fibe
- Page 408 and 409: Clinical ConsiderationIt is suggest
- Page 410 and 411: Clinical ConsiderationNeuropathic p
- Page 412 and 413: Wound HealingThe NS plays an import
- Page 414 and 415: Clinical ConsiderationNeural and ci
- Page 416 and 417: Compression SyndromesAlthough perip
- Page 418 and 419: Pathophysiological ConsiderationIf
- Page 420 and 421: Pathophysiological ConsiderationUni
- Page 422 and 423: Clinical ConsiderationAs is the cas
- Page 424 and 425: Pathophysiological ConsiderationFas
- Page 426 and 427: Damasio AR, Grabowski TJ, Bechara A
- Page 428 and 429: Magee DJ (2008) Orthopedic physical
- Page 430 and 431: Stecco C, Porzionato A, Macchi V et
- Page 432 and 433: CHAPTER 5Wound healing and scarsNev
- Page 434 and 435: Wound HealingWound healing, a compl
- Page 436 and 437: Table 5.1Stages of wound healing
Pathophysiological consideration
Elevated concentrations of biochemical substances associated with pain, inflammation and intercellular signaling are
found at active MTrP locations (e.g. inflammatory mediators, neuropeptides, catecholamines, pro-inflammatory
cytokines, pain modulators). Increased levels of pain modulators, such as Substance P and bradykinins, are plausible
explanations for the occurrence of pain associated with active MTrPs (Shah et al. 2005).